MRNA doses 12x-50x the vaccine dose CVAC requires - will be a Competitive advantage for $CVAC in terms of dose output. “mRNA-1273
Participants will receive 1 intramuscular (IM) injection of 100 microgram (ug) mRNA-1273 on Day 1 and on Day 29.”

“What makes CureVac different from the rivals in this race is dosage. The biotech is testing single-digit micrograms — 2, 4, 6 and 8 — in Phase I. And Haas says that the added potency of their vaccine should make it effective at extremely low dosing, something that would allow them to go further without scaling up like the high-dosage vaccines that are in development now.

CVAC has a GMP3 facility producing vaccine at risk. And Haas says they plan to add a group of additional GMP3 facilities in Q2 of next year, likely clustered together, which can produce hundreds of millions of doses for delivery in 2021, as they boot up a new GMP4 facility to handle the large production quantities for future use of their mRNA products — which extend into a variety of areas, including oncology.”

CVAC CEO (contd Endpoints article) “Haas says he expects CureVac will be ready to read out the Phase I data on its coronavirus vaccine around September or October. And they’ll quickly vault into a new study for the elderly as well as the big pivotal study with 20,000 to 30,000 subjects, ramping up enrollment by the end of this year. That will set up a near-term strategy to get up and operating with commercial supplies in a matter of months.“

CVAC ”CEO Franz-Werner Haas outlined plans to start a pivotal study before the end of this year, with a timeline that puts them in play for an emergency use authorization in Q1 of next year. And they are working out delivery deals now.”

https://endpts.com/3-weeks-3-big-investments-capped-by-a-213m-ipo-bring-curevacs-instant-cash-raise-to-a-cool-billion-dollars/

CVAC
“CureVac’s vaccines — which have never made it to approval but have some trial data backing them — can be made in 1 microgram doses, they can be made much faster than, say, Moderna’s vaccines. Hoerr says they could build millions of doses by summer, when they hope to start trials, and over a billion in a year or year and half.”

All MRNA Caccines are Not the same.


https://endpts.com/curevacs-ingmar-hoerr-tells-us-why-he-returned-to-take-on-a-pandemic-ngm-loses-a-president/

TSLA -CVAC https://www.fiercepharma.com/manufacturing/curevac-teaming-up-tesla-to-make-rna-microfactories-for-covid-19-shot
(H/T Mick-thanks)

CVAC happy to have a foothold on this best of Class (US Govt tried to buy- Germany, Bill Gates, and $GSK have stakes) Vaccine maker to the EU and world - when news out this PM of Big Pharma distribution negotiations 75 on Monday seems realistic.

CureVac in talks with pharma companies about partnership - Sueddeutsche
August 14, 2020, 12:28 pm
FRANKFURT, Aug 14 (Reuters) - German biotechnology firm CureVac is in talks with large drugmakers about a partnership to help market and distribute its prospective vaccine against the COVID-19 virus, its chief executive told Sueddeutsche Zeitung.

CureVac, backed by Microsoft founder and billionaire Bill Gates, listed on the Nasdaq stock market on Friday, raising $213 million.

Now have 3 Gammacore migraine patents doing well- it works in my hands. ECOR

CVAC
- german Vaccine maker -US Government t tried to buy - I just initiated -
like getting $NVAX in the 40s.

ECOR ”Electrical stimulation of the carotid sinus (Gammacore) lowers arterial pressure and improves heart rate variability..” Proof of Concept!

https://scholar.google.com.hk/scholar?start=10&q=vagal+stimulation+and+acetylcholine&hl=en&as_sdt=0,33&as_ylo=2020#d=gs_qabs&u=%23p%3D4et4CRJkW3wJ

2 8/14 BUY Ratings for ECOR - BTIG and Wainwright - no wonder it’s Down (?!?)

Just Another MAYO MONDAY (that’s my fun day - the HGEN price is gonna run day)

ECOR - Electrocore (ECOR) received a Buy rating and a $3.50 price target from BTIG analyst Ryan Zimmerman today. The company’s shares closed last Thursday at $2.26.

According to tipranks.com/, Zimmerman is a 5-star analyst with an average return of 13.6% and a 57.8% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Electrocore with a $3.33 average price target.

“Could one of these drugs be the next emergency treatment for COVID-19?“

“National Institute of Allergy and Infectious Diseases seems to agree that the drug, which is currently being tested in Arizona, has potential.

“The NIAID selected lenzilumab for a Big Effect Trial, which is a late-stage test of how effective drugs are against COVID-19”

“Because lenzilumab takes a big swing at cytokine storms, it has the potential to help some of the sickest patients, according to Durrant.“ HGEN CEO



https://www.google.com/amp/s/amp.azcentral.com/amp/5572046002

ECOR had an 8 cent Beat.
(can you feel the best within your heart”)

https://m.benzinga.com/article/17080419

ECOR 8 cent Beat.
(can you feel the best within your heart”)

https://m.benzinga.com/article/17080419

ECOR UP 450%! "Second quarter (2020) underwriting fees of $93.6 million, increased more than 450%, compared to the second quarter of 2019."

https://www.fool.com/earnings/call-transcripts/2020/07/22/evercore-inc-evr-q2-2020-earnings-call-transcript.aspx

Third Q will be the best ever at $1250 per Gammacore plus presciption fees.

Added another 10K shares -I know hold 130 K shares - easiest trade I ever made

ECOR provides Immunosuppresive Acetocholne Bitches- ABBV and PFE interested

HGEN Buy the Dip and CEO will throw in the MAYO Data!

ECOR Short ACETYLCHOLINE FRY smells so good.

ECOR will be a $50 stock on its Acetylcholine production - protective in COVID lung disease and other other viral disease. Feel free to ask why.

Take CEO to the Bank- he promised data that has him excited - he’s reliable based on past declarations -

HGEN CEO will spread the MAYO data on Thick - sellers locking in their bacon but without the MAYO

On HGEN- “After the SARS-CoV-2 infection, CD4+ T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc. The cytokines environment induces inflammatory CD14+CD16+ monocytes with high expression of IL-6 and accelerate the inflammation. Given that large amount of inflammatory cells infiltrations have been observed in lungs from severe COVID-19 patients7, 8, these aberrant pathogenic Th1 cells and inflammatory monocytes may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality. Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology. Thus, we suggest that monoclonal antibodies targeting GM-CSF may be effective in blocking inflammatory storms and, therefore, be a promising treatment of severe COVID-19 patients“



https://scholar.google.com.hk/scholar?as_ylo=2019&q=GM+CSF+COVID+19&hl=en&as_sdt=0,33#d=gs_qabs&u=%23p%3Dip5xng9X7KwJ

ECOR Gammacore reduces Lung Inflammation by releasing Acetylcholine in Viral Disease:
Vagal stimulation releases its neurotransmitter acetylcholine (ACh) https://res.mdpi.com/d_attachment/ijms/ijms-19-02466/article_deploy/ijms-19-02466.pdf -it’s receptor -a7nAchR’s -agonist decreased the pulmonary LPS-induced inflammatory response and reversed the inflammatory profile, particularly regarding M1 and M2 polarization, while also improving lung function and remodeling in a model of acute lung injury Based on these findings and those in the current study, we hypothesize that ACh produced by cholinergic lymphocytes acts on macrophages to decrease pro-inflammatory cytokine release and initiate tissue repair during the recovery phase of respiratory viral infection.
https://scholar.google.com.hk/scholar?as_ylo=2016&q=vagal+stimulation+an

Can you hear the BEAT within my hear?
ECOR tmrw.

Good HGEN B.E.T. - Added another 7K @$3.55 while you’re all talking amongst yourselves -now 127K shares

My Gammacore- My source of ECOR news - now over 130K shares- Your’s?

I’m a physician with a Gammacore unit - works on migraine via Vagus Nerve (10th Cranial Nerve) so why Wouldn’t it work on respiration -a major function of nerve X? It will - that’s why I own 130K shares.

Since direct anti IL-6 monoclonal antibodies -Actemra and Kevzara- failed - all that’s left for COVID ARDS therapy is the anti GM-CSF monoclonal antibody - HGEN Lenzilumab - snooze and lose.

https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1

Why HGEN gets its EUA for COVID ARDS (h/t MWM) “ Here we show that after the 2019-nCoV infection, CD4+T lymphocytes are rapidly activated to become pathogenic T helper (Th) 1 cells and generate GM-CSF etc. The cytokines environment induces inflammatory CD14+CD16+ monocytes with high expression of IL-6 and accelerates the inflammation. These aberrant and excessive immune cells may enter the pulmonary circulation in huge numbers and play an immune damaging role to causing lung functional disability and quick mortality. Our results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology. Therefore, we suggest that monoclonal antibody that targets the GM-CSF or interleukin 6 receptor may potentially curb immunopathology caused by 2019-nCoV and consequently win more time for virus clearance.”

https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1

COVID 19 will be spiking in Sept-Oct and will be confused with Flu just as ECOR is receiving its respiratory EUA for HOME and hospital use based on Spanish and Allegheny General study data - Perfect Storm.

964K HGEN Share Acquisition Statement SEC 13D 8/12 Flexpoint

https://sec.report/Document//?_gl=1*11vvqwb*_ga*Rk5aa3pvSkptX19QR19Ecjljd1dsejdabER6dGZGc1NOMmdBNGcxWjFnTkJxQnNjV0Y4ZURjNEVCSEVLYjhtQw..

2 weeks post Study Completion Date of a 90 patient trial of ECOR Gammacore as prevention of Mechanical Ventilation in COVID Lung Disease can trigger immediate EUA for ARDS.





Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)
Actual Study Start Date :
April 20, 2020
Estimated Primary Completion Date :
July 31, 2020
Estimated Study Completion Date :
July 31, 2020

ECOR will rise or fall on An EUA for a ARDS - which will be decided on the basis of the Spanish and Pennsylvania data - to come sometime between Aug and October - depending on interim reporting - primary endpoint of 90 patient study is in September. ARDS is 10x more prevalent in COVID19 than is asthma - popped to $3.30 on asthma - so carry the one....

The Russians Also Approved Avigan in a minute. -Right after they bought a truckload - Egypt dropped iit from trials- not even big in Japan.

VNS for COVID Cytokine Storm - “Through the wide innervation of the organism by the vagus nerve, especially the lungs and gastrointestinal tract, VNS appears as a serious candidate for a few side effect treatment that could dampen or prevent the cytokine storm observed in COVID-19 patients with severe symptoms”

ECOR

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387121/

“The importance of postcovid medical review for a full recovery” “The team of the Functional and Sports Unit has established this specific program that addresses all these processes globally and comprehensively. “This allows us to achieve a more complete recovery through treatment strategies specifically aimed at reversing the inflammatory process, neurovegetative and immune dysfunction, as well as peripheral and central neurological sensitization as processes that perpetuate the pathophysiological alterations of the muscles and the nervous and immune systems, “says Dr. Ríos.”
“Dr. De Teresa relates that they are «using bioelectric signal transmission devices (Gammacore) producing anti-inflammatory effects, vagal stimulation (with reversal of neurovegetative and hypothalamic-pituitary dystonia), and analgesic and desensitizing effects”

https://www.google.com/amp/s/www.explica.co/the-importance-of-postcovid-medical-review-for-a-full-recovery/amp/
ECOR